Dihydroartemisinin + piperaquine

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

EMLc | ATC codes: P01BF05

Indication	Malaria due to Plasmodium vivax ICD11 code: 1F41
Medicine type	Chemical agent
List type	Core
Formulations	**Oral > Solid > dispersible tablet:** 20 mg + 160 mg (phosphate) (EMLc) ; 40 mg + 320 mg (phosphate) (EMLc) **Oral > Solid > tablet:** 40 mg + 320 mg (phosphate) ; 20 mg + 160 mg (phosphate) ; 60 mg + 480 (phosphate) ; 80 mg + 640 mg (phosphate)
EML status history	First added in 2017 (TRS 1006) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Dihydroartemisinin + piperaquine
DrugBank	Artenimol, Piperaquine

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of two new strengths of tablets (60mg + 480 mg and 80 mg + 840 mg) on the EML and EMLc; - the addition of two new strengths of dispersible tablets (20 mg + 160 mg and 40 mg + 320 mg) on the EMLc; - removal of the weight restriction, in recognition that use should be in line with recommendations with WHO guidelines; - to update the listing to include reference to the phosphate salt of piperaquine in the formulation description instead of the medicine name.